United Therapeutics (NASDAQ:UTHR) Reaches New 1-Year High – Here’s What Happened

United Therapeutics Corporation (NASDAQ:UTHR) reached a new 52-week high on Wednesday . The stock traded as high as $519.99 and last traded at $510.44, with a volume of 382750 shares trading hands. The stock had previously closed at $513.79.

Analyst Ratings Changes

A number of research firms have recently weighed in on UTHR. Oppenheimer lifted their price objective on United Therapeutics from $510.00 to $575.00 and gave the company an “outperform” rating in a research report on Friday, September 5th. Royal Bank Of Canada increased their price objective on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a report on Thursday, October 30th. Morgan Stanley set a $447.00 target price on United Therapeutics in a research report on Wednesday, October 29th. Cantor Fitzgerald lifted their price objective on shares of United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 10th. Finally, Bank of America lifted their price target on United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 2nd. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $505.00.

United Therapeutics Trading Down 0.7%

The stock has a market cap of $21.98 billion, a PE ratio of 19.34, a P/E/G ratio of 5.10 and a beta of 0.86. The business’s 50-day moving average price is $466.64 and its 200-day moving average price is $384.02.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The firm had revenue of $799.50 million for the quarter, compared to the consensus estimate of $812.87 million. During the same quarter in the prior year, the company posted $6.39 earnings per share. The company’s revenue for the quarter was up 6.8% compared to the same quarter last year. As a group, analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction on Monday, October 6th. The stock was sold at an average price of $450.24, for a total value of $10,130,400.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold a total of 599,664 shares of company stock valued at $274,775,331 in the last quarter. Company insiders own 10.30% of the company’s stock.

Hedge Funds Weigh In On United Therapeutics

A number of institutional investors have recently added to or reduced their stakes in UTHR. Chung Wu Investment Group LLC acquired a new position in shares of United Therapeutics in the 2nd quarter valued at $29,000. WealthCollab LLC raised its holdings in United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 38 shares during the period. Rakuten Securities Inc. lifted its position in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 46 shares during the last quarter. SVB Wealth LLC purchased a new position in United Therapeutics during the first quarter worth about $32,000. Finally, Wilmington Savings Fund Society FSB increased its position in shares of United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 49 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.